Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient:: insights into structural requirements for kininogen expression

被引:20
作者
Krijanovski, Y
Proulle, V
Mahdi, F
Dreyfus, M
Müller-Esterl, W
Schmaier, AH
机构
[1] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[3] Hop Bicetre, AP HP, Fac Med Paris Sud, Paris, France
[4] Univ Frankfurt, Dept Biochem 2, D-6000 Frankfurt, Germany
关键词
D O I
10.1182/blood-2002-11-3329
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 6-year-old male with vertebral-basilar artery thrombosis was recognized to have high-molecular-weight kininogen (HK) deficiency. The propositus had no HK procoagulant activity and antigen (< 1%). Using monoclonal antibodies (Mabs) to kininogen domain 3, the propositus, family members, and Fitzgerald plasma were determined to have detectable low-molecular-weight kininogen. Mabs to HK domains 5 and 6 do not detect HK antigen in the propositus' plasma. The propositus has a single base pair (bp) deletion in cDNA position 1492 of exon 10 affecting amino acid 480 of the mature protein and resulting in a frameshift and a premature stop codon at position 1597 (amino acid 532). Unexpectedly, Mabs to the heavy chain and domain 5 of HK detect a 92-kDa form of HK in Fitzgerald plasma, the first HK-deficient plasma. The 92-kDa Fitzgerald HK has amino acid residues through 502, corresponding to domains 1 through 5, but lacks epitopes of domain 6 (positions 543 to 595). Fitzgerald DNA has a normal exon 10, but a 17-bp mutation in intron 9. These combined results indicate that mutations in the kininogen gene may differentially affect biosynthesis, processing, and/or secretion of HK. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:4430 / 4436
页数:7
相关论文
共 35 条
[1]  
Alhenc-Gelas M, 1999, THROMB HAEMOSTASIS, V81, P506
[2]  
CHEUNG PP, 1993, J BIOL CHEM, V268, P23361
[3]   WILLIAMS TRAIT - HUMAN KININOGEN DEFICIENCY WITH DIMINISHED LEVELS OF PLASMINOGEN PROACTIVATOR AND PREKALLIKREIN ASSOCIATED WITH ABNORMALITIES OF HAGEMAN FACTOR-DEPENDENT PATHWAYS [J].
COLMAN, RW ;
BAGDASARIAN, A ;
TALAMO, RC ;
SCOTT, CF ;
SEAVEY, M ;
GUIMARAES, JA ;
PIERCE, JV ;
KAPLAN, AP .
JOURNAL OF CLINICAL INVESTIGATION, 1975, 56 (06) :1650-1662
[4]   Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis [J].
Colman, RW ;
Jameson, BA ;
Lin, YZ ;
Johnson, D ;
Mousa, SA .
BLOOD, 2000, 95 (02) :543-550
[5]  
DELACADENA RA, 1987, J LAB CLIN MED, V109, P601
[6]   Bradykinin and its metabolite, Arg-Pro-Pro-Gly. Phe, are selective inhibitors of alpha-thrombin-induced platelet activation [J].
Hasan, AAK ;
Amenta, S ;
Schmaier, AH .
CIRCULATION, 1996, 94 (03) :517-528
[7]   MAPPING THE CELL-BINDING SITE ON HIGH-MOLECULAR-WEIGHT KININOGEN DOMAIN-5 [J].
HASAN, AAK ;
CINES, DB ;
HERWALD, H ;
SCHMAIER, AH ;
MULLERESTERL, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (33) :19256-19261
[8]  
HAYASHI H, 1990, BLOOD, V75, P1296
[9]   Mapping of the discontinuous kininogen binding site of prekallikrein - A distal binding segment is located in the heavy chain domain A4 [J].
Herwald, H ;
Renne, T ;
Meijers, JCM ;
Chung, DW ;
Page, JD ;
Colman, RW ;
MullerEsterl, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (22) :13061-13067
[10]  
JIANG YP, 1992, J BIOL CHEM, V267, P3712